Organovo Holdings, Inc. (ONVO) - NYSEMKT
  • Mon, Jul. 11, 9:15 AM
    | Mon, Jul. 11, 9:15 AM
  • Mon, Jul. 11, 8:51 AM
    • Micro cap Organovo (NYSEMKT:ONVO) is up 10% premarket on increased volume in response to is announcement of positive preclinical results generated with its 3D bioprinted human liver tissues.
    • The data, published in the journal PLOS One, showed Organovo's product was able to detect significant dose-dependent toxicity of trovafloxacin at clinically relevant doses compared to levofloxacin, a structurally similar but non-toxic compound. The hepatotoxicity of trovafloxacin, a broad based antibiotic launched by Pfizer (NYSE:PFE) but later withdrawn from the market because of the risk of serious liver damage, was not originally identified by traditional preclinical tests, including animal studies.
    • The study was funded by Organovo and Roche Pharmaceuticals (OTCQX:RHHBY).
    | Mon, Jul. 11, 8:51 AM | 17 Comments
  • Oct. 2, 2015, 9:12 AM
    | Oct. 2, 2015, 9:12 AM | 1 Comment
  • Sep. 29, 2015, 3:31 PM
    • 3D printer makers 3D Systems (DDD -6.8%), Stratasys (SSYS -9.3%), and Voxeljet (VJET -12.6%) are having another ugly day as markets remain in risk-off mode - the Nasdaq is down 1.2% - and so is 3D-printed tissue developer Organovo (ONVO -14.1%). Save for Voxeljet, volume has been below-average.
    • 3D Systems and Voxeljet have made fresh 52-week lows. YTD performances: DDD -33%, SSYS -69%, VJET -48%, ONVO -64%.
    • Though many shorts undoubtedly now have big paper profits, Voxeljet is the only name in the group to see significant short-covering this year: 3D had 34% of its float shorted as of Sep. 15, Stratasys 28%, Voxeljet 10%, and Organovo 27%.
    | Sep. 29, 2015, 3:31 PM | 8 Comments
  • Sep. 15, 2015, 12:41 PM
    | Sep. 15, 2015, 12:41 PM | 2 Comments
  • Sep. 1, 2015, 4:04 PM
    • Continuing a rough 2015, 3D Systems (DDD -6.6%), Stratasys (SSYS -5.8%), Organovo (ONVO -10.6%), Arcam (OTCPK:AMAVF -6.1%), and Voxeljet (VJET -4.9%) have seen outsized losses on a day the Nasdaq fell 2.9%. Volume was generally below-average.
    • Short interests indicate many shorts with large profits have chosen not to cover: 3D Systems had 35% of its float shorted as of Aug. 14, Stratasys 28%, Organovo 26%, and Voxeljet 11%.
    • Earlier today, Stratasys announced the Objet30 Dental Prime, a 3D printer aimed at smaller dental labs. The company promises the printer's High Quality mode can deliver "intricate, delicate features required for precise fittings on crown, bridge, and prosthetic models" via 16-micron layers.
    • Meanwhile, Organovo CEO Keith Murphy defended his company in a talk with Benzinga - he discussed partnerships with Merck, L'Oreal, and Yale, and downplayed Organovo's FQ1 numbers. "We reported about $300K in revenue for the first quarter, and we're seeing some reaction to that, I would say. The bigger picture is, last quarter we had $2 million in booked contracts. The fact that these (contracts) take a couple of quarters to be recognized as revenue shouldn't surprise anyone."
    | Sep. 1, 2015, 4:04 PM | 14 Comments
  • Aug. 11, 2015, 12:45 PM
    | Aug. 11, 2015, 12:45 PM
  • Aug. 11, 2015, 9:16 AM
    | Aug. 11, 2015, 9:16 AM
  • Aug. 11, 2015, 8:18 AM
    • Regenerative medicine firm Organovo (NYSEMKT:ONVO) slumps 19% in premarket trading on mediocre volume in response to its release of fiscal Q1 results after the close yesterday.
    • Although the company stated that contract bookings for its exVive3D Human Liver Tissue were ~$2M, recorded revenues were only ~$300K, far below the projected "tens of millions" eventual run rate that management believes is achievable.
    • Previously: Organovo says liver tissue will be $100M business (March 13)
    | Aug. 11, 2015, 8:18 AM | 11 Comments
  • Jun. 18, 2015, 9:22 AM
    | Jun. 18, 2015, 9:22 AM | 2 Comments
  • Jun. 18, 2015, 7:47 AM
    • Organovo (NYSEMKT:ONVO) announces that it intends to offer common shares for public sale pursuant to a shelf registration. The number of shares, price and terms have yet to be determined.
    • Shares are down 9% premarket on average volume.
    • Prospectus
    | Jun. 18, 2015, 7:47 AM | 37 Comments
  • Jun. 17, 2015, 5:37 PM
    | Jun. 17, 2015, 5:37 PM | 1 Comment
  • Apr. 22, 2015, 12:45 PM
    | Apr. 22, 2015, 12:45 PM
  • Apr. 22, 2015, 9:15 AM
    | Apr. 22, 2015, 9:15 AM
  • Apr. 22, 2015, 8:50 AM
    • Organovo (NYSEMKT:ONVO) enters into a multi-year collaboration agreement with Merck (NYSE:MRK) to develop multiple custom tissue models. The deal includes access to ONVO's exVive3D Human Liver Tissue service. Financial terms are not disclosed.
    • ONVO is up 17% premarket on robust volume.
    | Apr. 22, 2015, 8:50 AM | 14 Comments
  • Apr. 15, 2015, 12:32 PM
    • Beaten-down/well-shorted 3D Systems (DDD +4.6%), Stratasys (SSYS +3.7%), Voxeljet (VJET +4.4%), and Organovo (ONVO +5.2%) are posting big gains. Volume has been slightly above-average for ONVO, normal for DDD and SSYS, and below-average for VJET. The Nasdaq is up 0.5%.
    • Meanwhile, 3D printing/manufacturing service provider ARC Group (ARCW +12.1%) is soaring after Brean reiterated a Buy rating, albeit while cutting its target by $13 to $12 (still over 2x yesterday's close). The firm thinks EBITDA margin can rise to 18% by year's end from a current 14%, and to "at least 20%" in 2016. It also thinks improving demand from the firearms could drive upside to its estimates.
    • The gains come amid NYC's 3D Print Week conference. Both 3D Systems and Stratasys' MakerBot unit (based in Brooklyn) have large presences. As does 3D printing software vendor Materialise (MTLS +2.5%), which is sponsoring the conference's 3D Print Fashion Show and providing a closing keynote.
    • Separately, MakerBot has announced a reseller deal with D&H Distributing, an SMB-focused IT distributor for education, healthcare, government, and manufacturing clients. And Stratasys proper has rolled out a new high-end system (the Objet1000 Plus) said to print parts 40% faster than its predecessor, and at a lower cost.
    • Last week: 3D Systems rallies towards $30
    | Apr. 15, 2015, 12:32 PM | 13 Comments
Company Description
Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can... More
Sector: Healthcare
Industry: Medical Laboratories & Research
Country: United States